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a b s t r a c t
Dihydroxyoxocholestenoic acids are intermediates in bile acid biosynthesis. Here, using liquid chroma-
tography e mass spectrometry, we conﬁrm the identiﬁcation of 7a,24-dihydroxy-3-oxocholest-4-en-26-
oic and 7a,25-dihydroxy-3-oxocholest-4-en-26-oic acids in cerebrospinal ﬂuid (CSF) based on compar-
isons to authentic standards and of 7a,12a-dihydroxy-3-oxocholest-4-en-26-oic and 7a,x-dihydroxy-3-
oxocholest-4-en-26-oic (where hydroxylation is likely on C-22 or C-23) based on exact mass measure-
ment and multistage fragmentation. Surprisingly, patients suffering from the inborn error of metabolism
cerebrotendinous xanthomatosis, where the enzyme CYP27A1, which normally introduces the (25 R)26-
carboxylic acid group to the sterol side-chain, is defective still synthesise 7a,24-dihydroxy-3-oxocholest-
4-en-26-oic acid and also both 25 R- and 25 S-epimers of 7a,12a-dihydroxy-3-oxocholest-4-en-26-oic
acid. We speculate that the enzymes CYP46A1 and CYP3A4 may have C-26 carboxylase activity to
generate these acids. In patients suffering from hereditary spastic paraplegia type 5 the CSF concen-
trations of the 7a,24- and 7a,25-dihydroxy acids are reduced, suggesting an involvement of CYP7B1 in
their biosynthesis in brain.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Bile acids are formed from cholesterol via enzyme catalysed
reactions through numerous intermediates [1]. These in-
termediates include cholestenoic acids, unsaturated C27 carboxylic
acids derived from cholesterol. 3b-Hydroxycholest-5-en-(25 R)26-
oic acid (CA5-3b-ol), the simplest cholestenoic acid, is be formed
by (25 R)26-hydroxylation of cholesterol followed by oxidation to
the (25 R)26 carboxylic acid; both reactions catalysed by the
enzyme cytochrome P450 (CYP) 27A1 (Fig. 1A). This acid is then
hydroxylated by CYP7B1 to give 3b,7a-dihydroxycholest-5-en-
(25 R)26-oic acid (CA5-3b,7a-diol). Once 7a-hydroxylated, the acid
is a substrate for the enzyme hydroxysteroid dehydrogenase (HSD)
3B7, which is a 3b-hydroxysteroid dehydrogenase D5,D4 isomerase,
giving the product 7a-hydroxy-3-oxocholest-4-en-(25 R)26-oic
acid (CA4-7a-ol-3-one) [2]. Alternatively, the two 7a-hydroxy
acids can be formed from 7a-hydroxycholesterol (C5-3b,7a-diol)
with (25 R)26-hydroxylation and carboxylation preceding or suc-
ceeding oxidation and isomerisation in the ring system (Fig. 1A). In
2010 Ogundare et al. reported the detection of CA5-3b-ol and CA4-
7a-ol-3-one in human cerebrospinal ﬂuid (CSF) and also partially
identiﬁed two dihydroxy-3-oxocholest-4-en-26-oic acids [3]. At
that time authentic standards were unavailable to exactly identify
the latter two acids. Ogundare et al. were able to identify C-7 as one
of the sites of hydroxylation but made only tentative suggestions of
the locations of the second hydroxy groups [3]. Since the study by
Ogundare et al. [3] others have conﬁrmed the presence of CA5-3b-ol
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Fig. 1. Intermediates in bile acid biosynthesis pathways. (A) Formation of dihydroxy-3-oxocholest-4-en-26-oic acids from cholesterol via the acidic, neutral and 25-hydroxylase
pathways [1,2]. In the acidic and neutral pathway stereochemistry at C-25 is assumed to be 25 R unless otherwise indicated. (B) Formation of (25 R)CA4-7a,24 S-diol-3-one and
(25 S)CA4-7a,24 S-diol-3-one via the 24 S-hydroxylase pathway (red box) [21] and of 25 S- and 25 R-epimers of CA4-7a,12a-diol-3-one in the absence of CYP27A1 [26] (gold box). For
simplicity the formation and hydrolysis of CoA-thioesters in the steps preceding and succeeding C-25 racemisation are not shown. (C) Latter steps of the acidic pathway proceeding
mostly in the peroxisome leading to the four diastereomers of CA4-7a,24-diol-3-one. In liver the dominant product is (25 R)CA4-7a,24 R-diol-3-one. The inset shows the formation
of (25 S)CA4-7a,24 R-diol-3-one from its CoA-thioester following C-25 racemisation. In CTX the enzyme CYP27A1 is deﬁcient, while in SPG5 CYP7B1 is deﬁcient. Abbreviations:
ACOX2: acyl-coenzyme A oxidase 2. AMACR: a-methylacyl-CoA racemase. BACS: bile acid-CoA synthetase. C: Cholestane. CA: Cholestanoic acid. CH25H: Cholesterol 25-hydroxylase.
CYP: Cytochrome P450. DBP: D-Bifunctional Protein. HSD3B7: 3b-Hydroxysteroid dehydrogenase type 7. LBP: L-Bifunctional protein. SPCx: Sterol carrier protein x. VLCS: Very long
chain Co-A synthetase. The dihydroxy-3-oxocholest-4-en-26-oic acids CA4-7a,25-diol-3-one, CA4-7a,12a-diol-3-one and CA4-7a,24-diol-3-one are colour coded green, gold and red,
respectively.
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and CA4-7a-ol-3-one in human CSF [4,5]. It is noteworthy that CA4-
7a-ol-3-one was detected by Nagata et al. in chronic subdural he-
matoma, but analytical methods of the time were insufﬁcient to
detect the acid in normal CSF [6], although Axelson et al. had found
it to be a normal constituent of human blood [7]. Note, with the
exception of 25-hydroxy acids, unless speciﬁcally stated otherwise
stereochemistry at C-25 is assumed to be 25 R.
Cholestenoic acids with a 3b-hydroxy-5-ene structure have
been shown to be ligands to the liver X receptors (LXRs) a and b,
CA5-3b,7a-diol displaying neuroprotective properties while its
epimer CA5-3b,7b-diol and CA5-3b-ol being neurotoxic [3,8,9]. CA4-
7a-ol-3-one is not a ligand to LXR, and the biological properties of
down-stream acids are unknown [9].
Here we describe the identiﬁcation and quantiﬁcation, using
enzyme-assisted derivatisation and liquid chromatography (LC) -
high resolution mass spectrometry (HRMS) with multistage frag-
mentation (MSn), of the dihydroxy-3-oxocholest-4-en-26-oic acids
reported earlier by Ogundare et al. in human CSF [3]. The current
study goes beyond that of Ogundare et al. [3], Saeed et al. and
Sch€ols et al. [4,5] in that we have speciﬁcally targeted multiply
hydroxylated acids, exploiting synthetic standards to conﬁrm,
where possible, identiﬁcations made by LC-HRMS(MSn) and per-
formed quantiﬁcation in CSF and in plasma.
2. Materials and methods
2.1. Materials
The reagents and solvents were as described in Abdel-Khalik
et al. [10]. The authentic standards of 3b,7a,24 S-trihydrox-
ycholest-5-en-(25 R)26-oic acid ((25 R)CA5-3b,7a,24 S-triol) and
3b,7a,25-trihydroxycholest-5-en-(25 R/S)26-oic acid (CA5-
3b,7a,25-triol) were from Avanti Polar Lipids Inc (Alabaster, AL).
Their 3-oxo-4-ene analogues, 7a,24 S-dihydroxy-3-oxocholest-4-
en-(25 R)26-oic acid ((25 R)CA4-7a,24 S-diol-3-one) and 7a,25-
dihydroxy-3-oxocholest-4-en-(25 R/S)26-oic acid (CA4-7a,25-diol-
3-one), were prepared by treatment with cholesterol oxidase from
Streptomyces sp (Sigma-Aldrich, Gillingham, Dorset UK) (Fig. 2).
All CSF and plasma samples were provided with written
informed consent and institutional review board (IRB) approval
and were collected according to the principles of the Declaration of
Helsinki. Control CSF (n¼ 42) was from previous studies performed
in Swansea, collected from subjects with no known genetic defect
in cholesterol biosynthetic or metabolic enzymes. CSF from cere-
brotendinous xanthomatosis (CTX, n¼ 6) patients was collected as
part of an IRB-approved study at Oregon Health & Science Uni-
versity (OHSU), Portland, OR (see Supplemental Table 1 for muta-
tion data). Plasma from CTX (n¼ 13) and CSF (n¼ 3) and plasma
(n¼ 2) from hereditary spastic paraplegia type 5 (SPG5) patients
were from earlier studies in Swansea [9] or provided by the Athens
Medical Center. Control plasma (n¼ 24), from subjects with no
known genetic defect in cholesterol biosynthetic or metabolic en-
zymes, was from a previous study in Swansea [10].
2.2. Sample preparation and analysis
Two hundred and ﬁfty mL of CSF was added dropwise to 2.1mL
of ethanol containing 2 ng of [2H7]24(R/S)-hydroxycholesterol, 2 ng
[2H7]22 R-hydroxycholest-4-en-3-one, 2 ng [2H7]7a-hydrox-
ycholesterol, 1.38 ng [2H6]7a,25-dihydroxycholesterol, 4 ng [2H6]
25-hydroxyvitamin D3 and 800 ng [2H7]cholesterol. Each sample
was sonicated for 5min, after which 0.65mL of water was added
dropwise while continuing to sonicate. Sonication was continued
for a further 5min. The solution was centrifugation at 2400 g, 4 C,
for 30min. The supernatant, now in 3mL of 70% ethanol, was
loaded onto a 200mg Certiﬁed Sep-Pak C18 column (Waters,
Elstree, Herts, UK). The 3mL eluate was combined with a column
wash of 4mL of 70% ethanol to give SPE1-Fr1 (7mL) in which
oxysterols including cholestenoic acids elute.
The oxysterol fraction was then derivatised and analysed as
described in Abdel-Khalik et al. [10]. In brief, the oxysterol fraction
above was divided into two equal sub-fractions A and B and
lyophilised. Each sub-fraction was reconstituted in 100 mL of
propan-2-ol. One mL of 50mM phosphate buffer pH 7 containing
0.26 u of cholesterol oxidase from Streptomyces sp (Sigma-Aldrich,
Gillingham, Dorset, UK) was added to sub-fraction A and incubated
for 1 h at 37 C. The reaction was quenched with 2mL of methanol.
Sub-fraction Bwas treated in an identical fashion but in the absence
of cholesterol oxidase. To each sub-fraction 150 mL of glacial acetic
acid was added followed by 190mg of [2H5]Girard P (GP) reagent as
the bromide salt to sub-fraction A and 150mg of [2H0]GP as the
chloride salt to sub-fraction B. The reaction proceeded at room
temperature overnight in the dark. Excess derivatisation reagent
was then removed by re-cycling solid phase extraction (SPE) on a
60mg Oasis HLB column (Waters, Elstree, Herts, UK). Each eluate
was diluted to half its organic content until 17.5% organic was
achieved at which point derivatised oxysterols including choles-
tenoic acids were bound to the column and unreacted GP reagent
was in the ﬂow-through. After a wash with 10% methanol, deriva-
tised oxysterols were eluted in 2mL of methanol. LC-HRMS(MS)n
was performed as described in Abdel-Khalik et al. [10] using a
Dionex Ultimate 3000 L C system (Dionex now Thermo Fisher Sci-
entiﬁc, Hemel Hempstead, UK) with a C18 Hypersil Gold column
(Thermo Fisher Scientiﬁc) and Orbitrap Elite mass spectrometer
(Thermo Fisher Scientiﬁc). Quantiﬁcation was by the isotope dilu-
tion method exploiting LC-HRMS data with [2H7]24(R/S)-hydrox-
ycholesterol and [2H7]22 R-hydroxycholest-4-en-3-one as internal
standards for sub-fractions A (with cholesterol oxidase) and B
(without cholesterol oxidase), respectively. Plasma samples were
prepared and analysed as described in Abdel-Khalik et al. [10] in a
similar manner to described above for CSF. Quality control (QC)
samples were prepared for plasma and CSF by combining aliquots
of control samples.
3. Results
3.1. Dihydroxy-3-oxocholest-4-en-26-oic acids in CSF
3.1.1. CA4-7a,24-diol-3-one
The authentic standard of [2H5]GP-derivatised (25 R)CA4-
7a,24 S-diol-3-one gave rise to two peaks in the LC-HRMS recon-
structed ion chromatogram (RIC) for its [M]þ ion at m/z 585.4059,
corresponding to the syn and anti conformers of the derivative
(Fig. 3A, lower panel). The more abundant conformer eluted at
almost the same retention time as a chromatographic peak in the
equivalent LC-HRMS RIC from human CSF (1.99min, Fig. 3A, upper
panel). The less abundant conformer was observed as a shoulder
(2.82min) to an unknown peak, CA4-7a,x-diol-3-one, in the CSF
sample (Fig. 3A). Note during the course of this study there was
some retention time drift as the recording of data was spread over
manymonths. However, therewas no change in the order of elution
of cholestenoic acids as assessed by recording of QC samples within
each batch of samples.
When fragmented GP-derivatised sterols give intense [M-Py]þ
ions due to loss of the pyridine (Py) ring (see Supplemental Fig. 1)
[11]. The [M-Py]þ ion when fragmented further gives structure
speciﬁc MS3 spectra. The MS3 ([M]þ/[M-Py]þ/, i.e.
585.4/501.3/) spectra acquired at 2.01min from the CSF sample
(Fig. 4A) and 2.06min from the authentic standard of (25 R)CA4-
7a,24 S-diol-3-one (Fig. 4B) were essentially identical. A base peak
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fragment-ion at m/z 427.3 is characteristic for the GP-derivatised
CA4-7a,24 S-diol-3-one structure. Note, MS3 spectra were gener-
ated in the ion-trap and fragment-ionmeasurements were accurate
tom/z ± 0.1 in most cases, hence, fragment-ion m/z data is given to
only one decimal place. By generating a multiple reaction moni-
toring (MRM)-like chromatogram 585.4/501.3/427.3 the syn
and anti conformers of CA4-7a,24-diol-3-one are resolved from the
chemical background of the CSF sample, the conformers are evident
as peak at 1.99 and 2.79min in Fig. 5A. The fragment-ionm/z 427.3,
probably results from loss of CO2þH2 (46 Da) from the [M-Py-CO]þ
ion at m/z 473.3 via a classical charge-remote fragmentation
mechanism [12] (Supplemental Fig. 1).
By analysing oxysterol sub-fractions A and B where sample is
treated with or without cholesterol oxidase (Fig. 3C upper and
lower panels, respectively) 3b-hydroxy-5-ene sterols can be
deconvoluted from their 3-oxo-4-ene analogues. In the CSF
samples analysed about 90% of the acids were in the CA4-7a,24-
diol-3-one form, about 10% as CA5-3b,7a,24-triol. In the present
study the concentration of CA4-7a,24-diol-3-one was determined
to be 0.3± 0.1 ng/mL (mean± standard deviation, SD, n¼ 42, see
Table 1). In the absence of an isotope labelled authentic standard for
the CA4-7a,24-diol-3-one, quantiﬁcation was against the internal
standard [2H7]22 R-hydroxycholest-4-en-3-one. The limit of quan-
tiﬁcation was 0.05 ng/mL. In a separate study using identical
methodology the concentration of CA4-7a,24-diol-3-onewas found
to be 0.4± 0.1 ng/mL, n¼ 15 [10]. While the current methodology
can differentiate between 7a- and 7b-hydroxy epimers, 24 S- and
24 R-hydroxy epimers and (25 R)26- and (25 S)26-carboxylate
epimers [13], the availability of an authentic standards of just one
diastereomer does not allow the deﬁnitive stereochemical identi-
ﬁcation of CA4-7a,24-diol-3-one or CA5-3b,7a,24-triol.
Fig. 2. Conversion of 3b-hydroxy-5-ene acids to their 3-oxo-4-ene analogues by cholesterol oxidase enzyme from Streptomyces Sp and derivatisation with [2H5]GP to give syn and
anti conformers. In CA5-3b,7a,24 S-triol and CA4-7a,24 S-diol-3-one R1¼OH and R2¼H. In CA5-3b,7a,25-triol and CA4-7a,25-diol-3-one R1¼H and R2¼OH (upper panel).
Structures of (25 S)CA4-7a,25-diol-3-one and its isomers (25 R)CA4-7a,25-diol-3-one, (25 R)CA4-7a,24-diol-3-one and (25 R)CA4-7a,12a-diol-3-one are shown in the lower panel.
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3.1.2. CA4-7a,25-diol-3-one
The authentic standard of CA5-3b,7a,25-triol was available only
as a racemic mixture of 25 R- and 25 S-epimers. When treated with
cholesterol oxidase to give CA4-7a,25-diol-3-one and derivatised
with [2H5]GP, four chromatographic peaks were observed in the LC-
HRMS RIC for the [M]þ ion at m/z 585.4059 (Fig. 3B, lower panel).
These peaks correspond to the syn and anti conformers of the 25 R-
and 25 S-epimers (Fig. 2). When CSF was analysed there was clear
evidence for the presence of CA4-7a,25-diol-3-one by the appear-
ance of a shoulder at 3.47min and a distinct peak at 4.38min
(Fig. 3B, upper panel). To enhance sensitivity, when CSF was pre-
pared for LC-HRMS the ﬁnal SPE eluate was lyophilised and
reconstituted in 90 mL of 60% methanol prior to injection on the LC
system. This resulted in a small retention time shift in comparison
to the authentic standard which was prepared in the absence of
matrix.
The MS3 ([M]þ/[M-Py]þ/, i.e. 585.4/501.3/) spectra ac-
quired at 3.47min for CSF (Fig. 4C) and at 3.60min for the authentic
standard of CA4-7a,25-diol-3-one (Fig. 4D) are essentially identical.
A base peak fragment-ion at m/z 455.3 is characteristic of GP-
derivatised CA4-7a,25-diol-3-one. By recording an MRM chro-
matogram 585.4/501.3/455.3 for control CSF (Fig. 5B), two
distinct peaks are observed at 3.47 and 4.38min allowing the reso-
lution of CA4-7a,25-diol-3-one from other isomers. The fragment-
ion at m/z 455.3 is, however, not unique to CA4-7a,25-diol-3-one
(Fig. 4), but the MS3 spectra recorded for peaks at 3.47 (Figs. 4C)
and 4.38min conﬁrmed their origin to be CA4-7a,25-diol-3-one. The
fragment-ionatm/z455.3 results fromthe lossofH2CO2 fromthe [M-
Py]þ ion, this is likely to be through (i) a combination of dehydration
(18 Da) and decarbonylation (28Da) with loss of CO from the GP
reagent and loss of the labile 25-hydroxy or 7a-hydroxy group, and/
or (ii) loss of the C26 acid group as H2O plus CO with the second
hydrogen abstracted from the C-25-hydroxy group. This reaction
could proceed via a 6-electron classical charge-remote fragmenta-
tionmechanism [12] (Supplemental Fig. 2). Aswas the situationwith
7a,24-dihydroxy acids, the majority (>90%) of the 7a,25-dihydroxy
acid was found to be as the 3-oxo-4-ene i.e. CA4-7a,25-diol-3-one.
In the current study the concentration of CA4-7a,25-diol-3-one in
CSF was determined to be 1.6± 0.4 ng/mL (Table 1). Quantiﬁcation
was against the internal standard [2H7]22 R-hydroxycholest-4-en-3-
one. The limit of quantitation was 0.02 ng/mL. In an independent
study using the same method the level of CA4-7a,25-diol-3-one in
CSF was found to be 3.0± 1.1 ng/mL [10].
3.1.3. CA4-7a,x-diol-3-one
Two peaks, probably corresponding to syn and anti conformers,
of a more abundant but unknown dihydroxyoxocholestenoic acid
isomer, CA4-7a,x-diol-3-one, were detected at 2.62 and 3.74min in
the LC-HRMS RIC from the CSF sample shown in Fig. 3C. As with the
7a,24- and 7a,25-dihydroxy acids, the unknown compound was
predominantly in the 3-oxo-4-ene form. Its concentration was
determined here to be 5.8± 1.5 ng/mL (Table 1) and in an earlier
study 9.2± 3.0 ng/mL [10]. Quantiﬁcation was against the internal
standard [2H7]22 R-hydroxycholest-4-en-3-one, assuming a similar
response factor to the authentic standards of the 7a,24 S- and
7a,25-dihydroxy acids. Based on this assumption the limit of
quantiﬁcation was 0.05 ng/mL. The MS3 ([M]þ/[M-Py]þ/) spec-
trum acquired at 2.61min (Fig. 4E) shows some similarity to the
fragmentation pattern to CA4-7a,24-diol-3-one (Fig. 4A and B) and
CA4-7a,25-diol-3-one (Fig. 4C and D). The pattern of fragment ions
at m/z 151.1 (*b1-12), 179.1 (*b3-28) and 231.1 (*c2-18 þ 2) is char-
acteristic of GP-derivatised 7-hydroxy-3-oxo-4-ene sterols, while in
the high m/z range the neutral losses [M-Py-18]þ (m/z 483.3), [M-
Py-28]þ (m/z 473.3), [M-Py-46]þ (m/z 455.3) are common to GP-
derivatised acids (Supplemental Fig. 3). A triad of fragment-ions
at m/z 419.3 ([M-Py-82]þ), 440.3 (M-Py-61) and 447.3 ([M-Py-54)
are distinctive of the unknown compound, CA4-7a,x-diol-3-one,
(Fig. 4E). These fragment-ions are suggested to correspond to loss of
H2CO2 and 2  H2O (82 Da); CO, NH, and H2O (61 Da), and 3 
H2O (54 Da) from the [M-Py]þ ion, respectively. A further
fragment-ion was observed at 465.3 [M-Py-36]þ indicating the
presence of at least two labile hydroxy groups, supporting the
Fig. 3. LC-HRMS RICs (585.4059 ± 10 ppm) corresponding to [M]þ ions of [2H5]GP
derivatised dihydroxy-3-oxocholest-4-en-26-oic acids. (A) Control CSF (upper panel),
authentic standard of (25 R)CA4-7a,24 S-diol-3-one (lower panel). (B) Control CSF
(upper panel), authentic standard of (25 R/S)CA4-7a,25-diol-3-one (lower panel). (C)
Control CSF (SPE1-Fr1A) treated with cholesterol oxidase followed by [2H5]GP reagent
(upper panel), control CSF (SPE1-Fr1B) treated with [2H0]GP reagent in the absence of
cholesterol oxidase (lower panel). In (C) the RICs for [2H5]GP derivatised and [2H0]GP
derivatised acids are plotted with the same y-axis. Data was acquired in the Orbitrap
analyser of the Orbitrap Elite instrument. Peaks corresponding to the dihydroxy-3-
oxocholest-4-en-26-oic acids CA4-7a,25-diol-3-one, CA4-7a,12a-diol-3-one, CA4-
7a,24-diol-3-one and CA4-7a,x-diol-3-one are colour coded green, gold, red and purple
respectively.
J. Abdel-Khalik et al. / Biochimie 153 (2018) 86e9890
suggestion of a dihydroxy-3-oxocholest-4-en-26-oic acid structure.
While one of the hydroxy groups is at C-7, most likely of 7a-ste-
reochemistry, the location of the second hydroxy group is more
difﬁcult to assign possibly at C-22, C-23 or less likely at C-27 (in
Supplemental Fig. 3 we have assigned the second hydroxy group to
C-23).
3.1.4. CA4-7a,12a-diol-3-one
A second pair of peaks corresponding to an unknown dihy-
droxyoxocholestenoic acid were detected at 4.17min and 4.62min
in the LC-HRMS RIC shown in Fig. 3C. This metabolite was
measured here at a concentration of 1.1± 1.1 ng/mL (Table 1). In a
separate study its concentration was determined to be 1.1± 0.9 ng/
mL [10]. Quantiﬁcationwas against the internal standard [2H7]22 R-
hydroxycholest-4-en-3-one, assuming a similar response factor to
the authentic standards of the 7a,24 S- and 7a,25-dihydroxy acids.
Based on this assumption the limit of quantiﬁcation was 0.05 ng/
mL. Analysis of CSF with and without cholesterol oxidase treatment
revealed that the analogous trihydroxycholestenoic acid was
essentially absent.
The MS3 ([M]þ/[M-Py]þ/) spectrum acquired at 4.16min
(Fig. 4F) reveals many similar fragment-ions to CA4-7a,24 S-diol-3-
one (Fig. 4A and B) and CA4-7a,25-diol-3-one (Fig. 4C and D). The
fragment-ion pattern of m/z 151.1 (*b1-12) and 179.1 (*b3-28) is
characteristic of 7-hydroxy-3-oxo-4-ene sterols and is observed in
each spectrum, however, fragment ions at m/z 209.1 (*b3þ2) and
279.2 (*c3þ2), observed in the spectrum of the unknown com-
pound shown in Fig. 4F, are characteristic of 7,12-dihydroxy-3-oxo-
4-ene sterols [14] (Supplementary Fig. 4). In the high m/z range of
this spectrum, a distinctive fragment-ion of m/z 422.3 is evident.
This is analogous to an abundant ion at m/z 392.3 characteristic of
7a,12a-dihydroxycholest-4-en-3-one (Supplemental Fig. 5) [14].
This fragment-ion corresponds to the neutral-loss of CO, NH and
2  H2O (79 Da) from the [M-Py]þ ion (Supplementary Fig. 4).
Based on the evidence above, the unknown dihydroxyox-
ocholestenoic acid is presumptively identiﬁed as 7a,12a-dihy-
droxy-3-oxocholest-4-en-26-oic acid (CA4-7a,12a-diol-3-one). By
generating a MRM chromatogram 585.4/501.3/422.3, CA4-
7a,12a-diol-3-one is highlighted eluting at 4.16 and 4.64min
(Fig. 5D). This further supports the identiﬁcation of CA4-7a,12a-
diol-3-one as empirical data shows that B- and C-ring hydrox-
ysterols usually elute later than side-chain hydroxysterols in our
chromatographic system. Unpublished data from a study of plasma
samples from patients with the peroxisomal disorder acyl-CoA
oxidase 2 (ACOX2) deﬁciency (Fig. 1A) where cholestenoic acids,
including 25 R- and unusually 25 S-epimers of CA4-7a,12a-diol-3-
one build-up, substantiates the identiﬁcation of the 25 R-epimer
of CA4-7a,12a-diol-3-one in the current study eluting at 4.16 and
4.64min.
7a,12a,25-Trihydroxycholest-4-ene-3,24-dione (C4-7a,12a,25-
triol-3,24-dione, see Supplemental Fig. 6), an intermediate in the
formation of bile acids from 25-hydroxycholesterol (C5-3b,25-diol)
[15], is an isomer of CA4-7a,12a-diol-3-one. An authentic standard
of this compound is not available and it is possible that it may give a
similar MS3 spectrum to that assigned to CA4-7a,12a-diol-3-one
and contribute to some of the ion-current at 4.17 and 4.62min.
Fig. 4. MS3 ([M]þ/[M-Py]þ/, i.e. 585.4/501.3/) spectra acquired in the analyses of control CSF (A, C, E & F) and authentic standards of (25 R)CA4-7a,24 S-diol-3-one (B) and
(25 R/S)CA4-7a,25-diol-3-one (D). The spectra conﬁrm the identiﬁcation of CA4-7a,24-diol-3-one in (A), of CA4-7a,25-diol-3-one in (C), of CA4-7a,x-diol-3-one in (E) and of CA4-
7a,12a-diol-3-one in (F). Data was acquired in the linear ion trap (LIT) analyser of the Orbitrap Elite hybrid instrument with an accuracy of m/z± 0.1 for most fragment-ions.
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3.2. Dihydroxy-3-oxocholest-4-en-26-oic acids in CSF from CTX
patients
CYP27A1 catalyses the (25 R)26-hydroxylation of cholesterol
and further oxidation of the (25 R)26-hydroxy group to a (25 R)26-
carboxyl group (Fig. 1A) [1,16]. Deﬁciency in CYP27A1, as observed
in patients suffering from CTX, leads to reduced synthesis of cho-
lestenoic acids and of the primary bile acid chenodeoxycholic acid
[9,17,18].
3.2.1. CA4-7a,24-diol-3-one, CA4-7a,25-diol-3-one, CA4-7a,12a-
diol-3-one and CA4-7a,x-diol-3-one
The LC-HRMSRICs ofm/z 585.4059, corresponding to the [M]þ ion
of dihydroxy-3-oxocholest-4-en-26-oic acids, recorded from CSF of
CTX patients (n¼ 6) gave rise to a different proﬁle of peaks to that
observed normally in CSF (cf. Fig. 6A and Fig. 3C). Numerous peaks of
unknown identity are evident in the chromatogram from the CTX
samples. However, by generating a total ion chromatogram (TIC) for
the LC-MS3 scan ([M]þ/[M-Py]þ/, i.e. 585.4/501.3/, Fig. 6B),
which highlights GP-derivatised compounds via the neutral-loss of
pyridine, peaks suggesting the presence of CA4-7a,24-diol-3-one
(1.86 and 2.58min) and of CA4-7a,12a-diol-3-one (3.74 and
4.28min)were detected. Note, the chromatograms depicted in Figs. 3
and 6 were recorded on different days, months apart, resulting in a
shift in retention times. However, chromatographic peaks were
correlated by recording QC samples with each batch of samples.
Despite shifts in retention time between QC samples, the order of
elution of monitored analytes did not change. Further evidence for
these two acids was provided by generating RICs for the MRM tran-
sitions 585.4/501.3/427.3,which highlights CA4-7a,24-diol-3-one
Fig. 5. LC-MS3 MRM transitions appropriate to (A) CA4-7a,24-diol-3-one, (B) CA4-7a,25-diol-3-one, (C) CA4-7a,x-diol-3-one and (D) CA4-7a,12a-diol-3-one from the analysis of a
control CSF sample. MRMs were generated from data acquired in the LIT analyser of the Orbitrap Elite hybrid instrument with an m/z window of ±0.4. Peaks are colour coded as in
Fig. 3.
Table 1
Concentrations of dihydroxy-3-oxocholest-4-en-26-oic acids in CSF.
Compound Control CSF, n¼ 42 CTX CSF, n¼ 6 SPG5 CSF, n¼ 3
Mean Median SD Mean Median SD Signiﬁcance1 Mean Median SD Signiﬁcance1
ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL CTX v Control ng/mL ng/mL ng/mL SPG5 v Control
CA4-7a,24-diol-3-one 0.30 0.30 0.08 0.10 0.10 0.02 P< 0.01 0.07 0.09 0.07 P< 0.01
CA4-7a,x-diol-3-one 5.83 5.65 1.49 ND ND NA P< 0.01 0.60 0.27 0.66 P< 0.01
CA4-7a,25-diol-3-one 1.60 1.51 0.44 ND ND NA P< 0.01 0.192 0.05 0.27 P< 0.01
(25 R)CA4-7a,12a-diol-3-one 1.11 0.82 1.10 0.49 0.29 0.60 P< 0.05 0.64 0.72 0.17 P> 0.05
(25 S)CA4-7a,12a-diol-3-one ND ND NA 0.12 0.09 0.11 P< 0.01 ND ND NA NA
Quantiﬁcation was made utilising LC-HRMS RICs with [2H7]22 R-hydroxycholest-4-en-3-one as the internal standard.
1. Mann-Whitney test.
2. From Ref. [9].
ND¼ not detected.
NA¼ not available.
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(Fig. 6C), and 585.4/501.3/422.3, which highlights CA4-7a,12a-
diol-3-one (Fig. 6F). Conﬁrmation of the presence of CA4-7a,24-diol-
3-one in CSF from CTX patients was achieved by acquisition of MS3
spectra at 1.91 and 2.52min (Fig. 7A and B) and comparisonwith the
spectrum of the authentic standard (Fig. 4B). Despite the low in-
tensity of the chromatographic peaks in Fig. 6, and henceMS3 spectra
in Fig. 7, fragment-ions atm/z 151.1 and 179.1 characteristic of the 7-
hydroxy-3-oxo-4-ene structure and m/z 427.3 characteristic of the
7,24-dihydroxy-3-oxocholest-4-en-26-oic acid are evident in theMS3
spectra of peaks eluting at 1.91 and 2.52min (Fig. 7A and B). CA4-
7a,24-diol-3-one was detected in each of the six CTX CSF samples
analysed at a concentration of 0.1± 0.02 ng/mL but signiﬁcantly
lower (p< 0.01,Mann-Whitney test) than in control CSF (0.3± 0.1 ng/
mL, Table 1).
The MS3 spectra of the chromatographic peaks at 3.74 and
4.28min (Fig. 6F) give similar patterns of fragment-ions to CA4-
7a,12a-diol-3-one present in normal CSF (cf. Fig. 7D and F with 4 F).
In addition to fragment-ions at m/z 151.1 and 179.1 the spectra
show a fragment-ion at m/z 422.3 characteristic of the 7,12-
dihydroxy-3-oxocholest-4-en-26-oic acids. Interestingly, four
chromatographic peaks were evident in Fig. 6F giving MS3 spectra
attributable to CA4-7a,12a-diol-3-one (Fig. 7CeF). Normally only
two chromatographic peaks are assigned to the CA4-7a,12a-diol-3-
one structure (Fig. 3C). The four peaks in the CTX sample are sug-
gestive of syn and anti conformers of the 25 R- and 25 S-epimers of
CA4-7a,12a-diol-3-one. A similar pattern of peaks was found in
plasma of patients suffering from ACOX2 deﬁciency (unpublished
data), where both epimers are expected, substantiating the current
identiﬁcation.
The 25 S-epimer of CA4-7a,12a-diol-3-one, corresponding to the
earlier eluting components in the twin pairs of peaks (3.60 and
4.10min in Fig. 6F), was found in CTX patients at a level of
0.1± 0.1 ng/mL, but in normal plasma was not detected (Table 1).
The 25 R-epimer was present in ﬁve of the six CTX patients studied
(0.5± 0.6 ng/mL) and in the other patient neither epimer was
detected. (25 R)CA4-7a,12a-diol-3-one was present at signiﬁcantly
lower levels in CTX CSF than in normal CSF (p< 0.05). The two
epimers are interconvertible via the enzyme alpha-methylacyl-CoA
racemase (AMACR) [1].
As mentioned above, C4-7a,12a,25-triol-3,24-dione, an inter-
mediate in the formation of bile acids from C5-3b,25-diol [15], is an
isomer of CA4-7a,12a-diol-3-one and may contribute some ion-
current to the peaks assigned to (25 R)CA4-7a,12a-diol-3-one.
However, C-25 is not asymmetric in C4-7a,12a,25-triol-3,24-dione
(Supplemental Fig. 6) and will not give epimers at C-25 and
cannot account for the peaks assigned to the (25 S)CA4-7a,12a-diol-
Fig. 6. Analysis of CSF from a CTX patient. (A) LC-HRMS RICs (585.4059± 10 ppm, upper panel; 580.3745± 10 ppm, lower panel). The upper panel shows CTX CSF (SPE1-Fr1A)
treated with cholesterol oxidase followed by [2H5]GP reagent, while the lower panel shows CTX CSF (SPE1-Fr1B) treated with [2H0]GP reagent in the absence of cholesterol oxidase.
The RICs for [2H5]GP derivatised and [2H0]GP derivatised acids are plotted with the same y-axis. Data was acquired in the Orbitrap analyser. (B) LC-MS3 (585.4/501.3/) TIC
appropriate to [2H5]GP derivatised dihydroxy-3-oxocholest-4-en-26-oic acids. LC-MS3 MRM transitions appropriate to (C) CA4-7a,24-diol-3-one, (D) CA4-7a,25-diol-3-one, (E) CA4-
7a,x-diol-3-one and (F) CA4-7a,12a-diol-3-one. In (D) and (E) the horizontal bars indicate where the targeted acids are expected to elute. The MRMs in (CeF) were generated from
data acquired in the LIT analyser of the Orbitrap Elite hybrid instrument with an m/z window of ±0.4. Chromatograms displayed in Fig. 5 and 6 were recorded on different days and
show a time shift of about 0.4min for the later eluting peaks. Retention times were correlated by the analysis of QC samples within in each sample batch. Peaks are colour coded as
in Fig. 3.
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3-one. Though at signiﬁcantly lower level than in normal CSF, (25 R)
CA4-7a,12a-diol-3-one was detected in CSF from CTX patients
despite CYP27A1 deﬁciency. Notably, C4-7a,12a-diol-3-one is also
elevated in CSF of CTX patients (data not shown) and could provide
a substrate for carboxylation at C-26.
Despite generating the MRM chromatogram
585.4/501.3/455.3 to highlight CA4-7a,25-diol-3-one there was
no evidence for this acid in CSF from CTX patients (Fig. 6D). The
most abundant dihydroxy-3-oxocholest-4-en-26-oic acids in hu-
man CSF, CA4-7a,x-diol-3-one and (Fig. 3C) was not detected in CSF
from CTX patients (Fig. 6E).
3.3. Dihydroxy-3-oxocholest-4-en-26-oic acids in CSF from SPG5
patients
Oxysterol 7a-hydroxylase (CYP7B1) catalyses the 7a-hydroxyl-
ation of most oxysterols [1,19,20]. Deﬁciency in this enzyme, as
observed in patients suffering from SPG5, leads to elevated levels of
C5-3b,25-diol, (25 R)26-hydroxycholesterol (C5-3b,26-diol) and
CA5-3b-ol and reduced levels of 7a,25-dihydroxycholesterol (C5-
3b,7a,25-triol), 7a,(25 R)26-dihydroxycholesterol (C5-3b,7a,26-
triol) and CA5-3b,7a-diol, and their 3-oxo-4-ene equivalents in
CSF [5,9]. Thus, dihydroxy-3-oxocholest-4-en-26-oic acids con-
taining a 7a-hydroxy group are predicted to be reduced in CSF from
SPG5 patients in comparison to healthy controls.
3.3.1. CA4-7a,24-diol-3-one, CA4-7a,25-diol-3-one, CA4-7a,12a-
diol-3-one and CA4-7a,x-diol-3-one
In 2014 we analysed CSF from SPG5 patients [9], but in the
absence of authentic standards of CA4-7a,24-diol-3-one or CA4-
7a,25-diol-3-one misidentiﬁed the former metabolite. Reassess-
ment of our earlier data [9], now with access to authentic stan-
dards, allows deﬁnitive identiﬁcation of CA4-7a,24-diol-3-one at a
concentration of 0.1± 0.1 ng/mL and of CA4-7a,25-diol-3-one at
0.2± 0.3 ng/mL (n¼ 3) (Table 1).
Although authentic standards are still not available for CA4-
7a,12a-diol-3-one, based on fragmentation data discussed above,
we identify (25 R)CA4-7a,12a-diol-3-one in SPG5 CSF at a concen-
tration of 0.6± 0.2 ng/mL and CA4-7a,x-diol-3-one at 0.6± 0.7 ng/
mL, these values are considerably lower than the values for control
CSF measured in this study (see Table 1). As in the case of control
CSF, the concentrations of trihydroxycholest-5-en-26-oic acids
were at most 20% of the analogous dihydroxycholest-4-en-26-oic
acids (Supplemental Figs. 7A and B).
3.4. Dihydroxy-3-oxocholest-4-en-26-oic acids in control plasma
Control plasma (n¼ 24) was from a previously published study
[10] and data from that study for dihydroxy-3-oxocholest-4-en-
26-oic acids was compared to new data for CTX and SPG5 patients.
CTX (n¼ 13) and SPG5 (n¼ 2) plasma was analysed in separate
batches on different days to avoid cross contamination from
abundant metabolites. However, in each sequence a QC sample
Fig. 7. MS3 ([M]þ/[M-Py]þ/, i.e. 585.4/501.3/) spectra from CSF of a CTX patient. The spectra conﬁrm the presence of dihydroxy-3-oxocholest-4-en-26-oic acids in CSF.
Spectra shown in (A) & (B) are of syn and anti conformers of CA4-7a,24-diol-3-one, (C) & (E) are interpreted as syn and anti conformers of (25 S)CA4-7a,12a-diol-3-one, and (D) & (F)
are interpreted as syn and anti conformers of (25 R)CA4-7a,12a-diol-3-one. Data was acquired in the LIT analyser of the Orbitrap Elite hybrid instrument with an accuracy of m/z ±
0.1 for most fragment-ions.
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was included in order to calibrate retention times to those in
control plasma.
3.4.1. CA4-7a,24-diol-3-one
In plasma collected from healthy controls (n¼ 24), CA4-7a,24-
diol-3-one was reported to be present at a concentration of
0.05± 0.04 ng/mL (Table 2, Fig. 8A) [10]. CA4-7a,24-diol-3-one was
more abundant than its 3b-hydroxy-5-ene analogue, CA5-3b,7a,24-
triol, by about 10-fold. Although present at low levels in plasma
(Fig. 8A and B), the identiﬁcation of CA4-7a,24-diol-3-one was
conﬁrmed by an acquisition of an MS3 spectrum at 1.74min as
shown Supplemental Fig. 8A.
3.4.2. CA4-7a,25-diol-3-one
CA4-7a,25-diol-3-one was determined to be the second most
abundant dihydroxy-3-oxocholest-4-en-26-oic acid in CSF, but was
only detected at trace levels in plasma (<0.05 ng/mL).
3.4.3. CA4-7a,x-diol-3-one
The LC-HRMS RIC for the [M]þ ion at m/z 585.4059 revealed
peaks at 2.26 and 3.20min assigned to the syn and anti conformers
of CA4-7a,x-diol-3-one (Fig. 8A). The identiﬁcation was conﬁrmed
by acquisition of MS3 spectra (Supplemental Figs. 8B and C).
Fragment-ions at m/z 151.1, 179.1 and 231.1 characteristic of the 7-
hydroxy-3-oxo-4-ene structure were evident. In the high m/z
range fragment ions atm/z 419.3, 440.3 and 447.3 were observed as
in the spectra recorded in CSF and annotated as CA4-7a,x-diol-3-
one (Fig. 4E). In control plasma, CA4-7a,x-diol-3-one was deter-
mined to be present at a concentration of 0.92 ± 0.30 ng/mL
(Table 2), more than ten-fold greater than the 3b-hydroxy-5-ene
analogue, CA5-3b,7a,x-triol [10].
3.4.4. CA4-7a,12a-diol-3-one
(25 R)CA4-7a,12a-diol-3-one is the most abundant dihydroxy-3-
oxocholest-4-en-26-oic acid in plasma [10]. Syn and anti con-
formers of the 25 R-epimer were assigned to peaks at 3.70 and
4.25min in the LC-HRMS RIC (Fig. 8A). MS3 spectra recorded at 3.70
and 4.28min conﬁrmed these identiﬁcations (Supplemental
Figs. 8D and E). Fragment-ions at m/z 151.1, 179.1, 209.1 and
279.2m/z were observed, as in the spectra assigned to CA4-7a,12a-
diol-3-one in CSF (Fig. 4F). In the high m/z range the fragment-ion
at m/z 422.3 was present which also agrees with the spectrum
recorded for CA4-7a,12a-diol-3-one in CSF. Plasma concentrations
of 1.56± 1.24 ng/mL were determined for CA4-7a,12a-diol-3-one in
control samples (Table 2), the 3b-hydroxy-5-ene analogue was at
least ten-fold less abundant. There was no evidence for the 25 S-
epimer in the control plasma samples analysed.
3.5. Dihydroxy-3-oxocholest-4-en-26-oic acids in plasma from CTX
patients
Plasma was analysed from 13 CTX patients.
3.5.1. CA4-7a,24-diol-3-one, CA4-7a,25-diol-3-one and CA4-7a,x-
diol-3-one
CA4-7a,24-diol-3-one was detected in CTX plasma at about the
limit of detection of the method (0.05 ng/mL) in 11 of the 13 sam-
ples analysed, in one other it was absent but was present at 0.35 ng/
mL in the other sample (Table 2). There was little evidence for the
presence of CA4-7a,25-diol-3-one or CA4-7a,x-diol-3-one in plasma
fromCTX patients. The absence of the two acids in plasma fromCTX
patients agrees with the inability to detect these dihydroxy-3-
oxocholest-4-en-26-oic acids in CSF from CTX patients.
3.5.2. CA4-7a,12a-diol-3-one
The RIC for m/z 585.4059 (Fig. 8C) gave two peaks at 4.15 and
4.68min and the MRM chromatogram of 585.4/501.3/422.3
(Supplemental Fig. 9) at 4.10 and 4.70min which are assigned to
(25 R)CA4-7a,12a-diol-3-one based on comparison of retention
time to a QC sample run in the same sample batch. The mean
concentration of (25 R)CA4-7a,12a-diol-3-one in CTX plasma
(0.29± 0.43 ng/mL) was signiﬁcantly lower than in healthy controls
(1.56± 1.24 p< 0.01, Table 2), and of the 13 CTX samples analysed
the acid was only identiﬁed in 8 samples. In 7 samples there was a
suggestion of the presence of the (25 S)-epimer but only at trace
levels (0.08± 0.12 ng/mL).
3.6. Dihydroxy-3-oxocholest-4-en-26-oic acids in plasma from
SPG5 patients
As was the case with CSF, plasma from SPG5 patients was ana-
lysed for dihydroxy-3-oxocholest-4-en-26-oic acids in a study
performed by us in 2014 [9], but in the absence of authentic stan-
dards. In the current study we have analysed plasma from a further
two patient samples.
3.6.1. CA4-7a,24-diol-3-one and CA4-7a,25-diol-3-one
A peak corresponding to CA4-7a,24-diol-3-one was observed at
1.85min in the LC-HRMS RIC for m/z 585.4059 (Fig. 8D) and at
1.82min the MRM chromatogram 585.4/501.3/427.3
(Supplemental Fig.10A) from analysis of SPG5 plasma, the retention
time being almost identical to that recorded for CA4-7a,24-diol-3-
one in a QC plasma sample run within in the same batch of sam-
ples (Supplemental Fig. 10B). The plasma levels of CA4-7a,24-diol-
3-one in the two SPG5 patients analysed here were 0.15 and
0.23 ng/mL, somewhat higher than levels seen in healthy controls
(0.05± 0.04 ng/mL, Table 2). There was no convincing evidence for
the presence of CA4-7a,25-diol-3-one in SPG5 plasma.
Table 2
Concentrations of dihydroxy-3-oxocholest-4-en-26-oic acids in plasma.
Compound Control plasma1, n¼ 24 CTX plasma, n¼ 13 SPG5 plasma
Mean Median SD Mean Median SD Signiﬁcance2 P1 P2
ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL CTX v Control ng/mL ng/mL
CA4-7a,24-diol-3-one 0.05 0.04 0.04 0.15 0.06 0.19 P> 0.05 0.23 0.15
CA4-7a,x-diol-3-one 0.92 0.89 0.30 ND ND NA P< 0.01 0.33 0.20
CA4-7a,25-diol-3-one ND ND NA ND ND NA NA ND ND
(25 R)CA4-7a,12a-diol-3-one 1.56 1.38 1.24 0.29 0.03 0.43 P< 0.01 1.91 0.78
(25 S)CA4-7a,12a-diol-3-one ND ND NA 0.08 0.03 0.12 P< 0.01 ND ND
Quantiﬁcation was made utilising LC-HRMS RICs with [2H7]22 R-hydroxycholest-4-en-3-one as the internal standard.
1.Data from Abdel-Khalik et al. [10].
2.Mann-Whitney test.
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3.6.2. CA4-7a,12a-diol-3-one
The LC-HRMS RIC for m/z 585.4059 (Fig. 8D) and MRM chro-
matogram 585.4/501.3/422.3 (Supplemental Fig. 10D) revealed
two peaks at 3.92 and 4.50min assigned to the syn and anti con-
formers of (25 R)CA4-7a,12a-diol-3-one. The concentrations of
(25 R)CA4-7a,12a-diol-3-one in the two SPG5 patients (1.91 and
0.78 ng/mL) were at similar levels to healthy controls, i.e.
1.56± 1.24 ng/mL (Table 2). No (25 S)CA4-7a,12a-diol-3-one was
detected.
3.6.3. CA4-7a,x-diol-3-one
In the LC-HRMS RIC for m/z 585.4059 (Fig. 8D) and the MRM
chromatogram 585.4/501.3/447.3 (Supplemental Fig. 10C) a
peak at 2.40min is evident which gives an MS3 spectrum
(Supplemental Fig. 8F) similar to that assigned to CA4-7a,x-diol-3-
one in CSF (Fig. 4E) and control plasma (Supplemental Fig. 8B). In
the low m/z range of the MS3 spectrum acquired from the SPG5
patient, fragment-ions at m/z 151.1, 179.1 and 231.1 were detected
while fragment ions m/z 419.3, 440.3 and 447.3 were detected in
the high m/z range. CA4-7a,x-diol-3-one was determined to be
present in plasma from SPG5 patients at concentrations of 0.33 and
0.2 ng/mL, lower than observed in any of the 24 healthy controls
(range 0.4e1.33 ng/ml, mean± SD 0.92± 0.30).
4. Discussion
Dihydroxy-3-oxocholest-4-en-26-oic acids are present in hu-
man CSF and plasma [3,9,10]. These consist of CA4-7a,24-diol-3-
one, CA4-7a,25-diol-3-one, CA4-7a,12a-diol-3-one and a fourth
acid CA4-7a,x-diol-3-one where the location of the second hydroxy
group is probably on the C17 side-chain. The concentrations of these
dihydroxy-3-oxocholest-4-en-26-oic acids in CSF follow the order
CA4-7a,x-diol-3-one> CA4-7a,25-diol-3-one> (25 R)CA4-7a,12a-
diol-3-one> CA4-7a,24-diol-3-one (Table 1). In plasma from
healthy controls the order is (25 R)CA4-7a,12a-diol-3-one> CA4-
7a,x-diol-3-one> CA4-7a,24-diol-3-one (Table 2) [10]. It is note-
worthy that the concentrations of CA4-7a,24-diol-3-one, CA4-
7a,25-diol-3-one and CA4-7a,x-diol-3-one are higher in CSF than
plasma, suggesting that they are formed, at least in part, in the
central nervous system (CNS). CA4-7a,24-diol-3-one could be
formed via two different pathways, (i) via the acidic pathway of bile
acid biosynthesis as depicted in Fig. 1A or (ii) via a pathway starting
with 24 S-hydroxylation of cholesterol by CYP46A1 (Fig. 1B) [21]. In
fact, all of the enzymes, or their transcripts [3], including AMACR
[22], required by the acidic pathway for biosynthesis of CA4-7a,24-
diol-3-one are expressed in brain. The latter steps of the acidic
pathway leading to the formation the diastereomers (25 R)CA4-
7a,24 S-diol-3-one, (25 R)CA4-7a,24 R-diol-3-one, (25 S)CA4-
7a,24 S-diol-3-one and (25 S)CA4-7a,24 R-diol-3-one are shown in
Fig. 1C [23]. The arm of the pathway catalysed by D-bifunctional
protein (DBP) is dominant in the liver leading to the formation of
the (25 R)CA4-7a,24 R-diol-3-one [2], however, the relative impor-
tance of this and the other arm catalysed by L-bifunctional protein
(LBP) leading to (25 S)CA4-7a,24 S-diol-3-one or (25 R)CA4-7a,24 S-
diol-3-one in the CNS is not known. Alternatively, a pathway
starting with 24 S-hydroxylation of cholesterol by CYP46A1, which
is highly expressed in brain [1], can lead to the biosynthesis of both
(25 R)CA4-7a,24 S-diol-3-one and also (25 S)CA4-7a,24 S-diol-3-
one (Fig. 1B). The second step in this pathway, 7a-hydroxylation
of 24 S-hydroxycholesterol (C5-3b,24 S-diol), is catalysed by
CYP39A1, which is only weakly expressed in brain [22]. However,
another route could be via (25 R)26-hydroxylation by CYP27A1 or
CYP46A1 [24] and subsequent (25 R)26-carboxylation (Fig. 1B),
before or after 7a-hydroxylation via CYP7B1, which is itself is highly
expressed in brain [20]. C5-3b,24 S-diol is a known substrate of
CYP27A1 [25]. Still yet another route for the formation of CA4-
7a,24 S-diol-3-one could start with 24 S-hydroxylation of 7a-
hydroxycholesterol (C5-3b,7a-diol) by CYP46A1 [24]. C5-3b,7a-diol
is not synthesised in brain butmay be imported from the periphery.
In the absence of additional authentic standards we cannot be
sure of the structure of CA4-7a,x-diol-3-one, but the MS3 frag-
mentation pattern suggests that the second hydroxy group is
Fig. 8. LC-HRMS RICs ±10 ppm appropriate to the analysis of [2H5]GP and [2H0]GP
derivatised dihydroxy-3-oxocholest-4-en-26-oic acids in control (A), CTX (C) and SPG5
(D) plasma. The RICs for [2H5]GP derivatised dihydroxy-3-oxocholest-4-en-26-oic acids
are plotted on the same y-axis scale as the RICs for [2H0]GP derivatised acids. (B) LC-
MS3 TICs appropriate to [2H5]GP and [2H0]GP derivatised dihydroxy-3-oxocholest-4-
en-26-oic acids in control plasma. Control, CTX and SPG5 plasma were analysed on
different days which causes a small deviation in retention time. Peaks were correlated
by recording QCs with each sample batch. HRMS data was recorded in the Orbitrap and
MS3 data in the LIT of the Orbitrap Elite hybrid instrument. Peaks are colour coded as in
Fig. 3.
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located on C-22 or C-23. CYP3A4 has 23 R-hydroxylase activity [26],
and is expressed in human brain [27].
Surprisingly, in both CSF and plasma from CTX patients CA4-
7a,24-diol-3-one and CA4-7a,12a-diol-3-one were detected, the
latter acid as both 25 S and 25 R-epimers. Shown in Fig. 1B is a
potential pathway for the formation of CA4-7a,12a-diol-3-one in
the absence of CYP27A1. CYP3A4 has been shown to have (25 S)26-
hydroxylase activity [26] and we speculate that the primary alcohol
formed could be oxidised further to a carboxylic acid by this
enzyme. In studies with recombinant human enzyme we have
conﬁrmed that CYP3A4 has (25 S)26-hydroxylase activity towards
C5-3b,7a-diol (unpublished data). Mast et al. noted that recombi-
nant CYP46A1 could further hydroxylate C5-3b,24 S-diol to 24 S,26-
dihydroxycholesterol (C5-3b,24 S,26-triol) [24], we speculate that
the enzyme may also oxidise C-26 to a carboxylic acid, which could
be metabolised further to 25 R- and 25 S-epimers of CA4-7a,24 S-
diol-3-one (Fig. 1B). CA4-7a,x-diol-3-one could not be detected in
CSF or plasma from CTX patients.
Analysis of CSF (Table 1) and plasma (Table 2) from SPG5 pa-
tients revealed that CA4-7a,24-diol-3-one, CA4-7a,25-diol-3-one,
(25 R)CA4-7a,12a-diol-3-one and CA4-7a,x-diol-3-one are formed
even in the absence of CYP7B1 activity, with 7a-hydroxylation
presumably being catalysed by CYP39A1 or CYP7A1 [28,29]. In CSF,
the concentrations of each of the four acids is reduced in SPG5
patients, although not to statistical signiﬁcance in the case of (25 R)
CA4-7a,12a-diol-3-one, indicating that CYP7B1 has a role in their
biosynthesis. In contrast to control samples where the concentra-
tions of CA4-7a,24-diol-3-one, CA4-7a,25-diol-3-one and CA4-7a,x-
diol-3-one are higher in CSF than plasma, the concentration of CA4-
7a,24-diol-3-one is higher in SPG5 plasma than CSF. This suggests
that CYP7B1 is important for the biosynthesis of CA4-7a,24-diol-3-
one in brain.
The biological relevance of the dihydroxy-3-oxocholest-4-en-
26-oic acids identiﬁed in this work is unknown. While cholestenoic
acids with a 3b-hydroxy-5-ene structure are ligands to LXRs, sterols
with a 3-oxo-4-ene group do not appear to activate these receptors.
Although we have only limited clinical data for the CTX and
SPG5 patients studied in this work the levels of the dihydroxy-3-
oxocholest-4-en-26-oic acids determined in CSF do provide
conﬁrmatory diagnostic biomarkers of the two diseases. Whether
or not the levels of these acids provide an indication of the severity
of disease requires further study.
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